RSC Advances
Paper
134.3, 132.7, 130.5, 129.3, 125.8, 124.0, 122.3, 120.6, 114.3, 61.2,
60.8, 40.0, 14.1; IR nmax/cmꢁ1 3323, 2978, 1716, 1618, 1491,
1461, 1375, 1069, 826, 752; HRMS (ESI-TOF) m/z: [M + H]+ calcd
for C18H18BrN2O2S 405.0267, found 405.0269.
Ethyl 2-(3-(3-chlorophenyl)-2-thioxo-1,2,3,4-tetrahydroquin-
azolin-4-yl)acetate (4i). Following the typical procedure above,
compound 4i (324 mg, 90%) was obtained as a white solid: mp
148–150 ꢀC; 1H NMR (400 MHz, CDCl3) d 9.23 (s, 1H), 7.43–7.26
(m, 5H), 7.16 (d, J ¼ 7.6 Hz, 1H), 7.07 (t, J ¼ 7.6 Hz, 1H), 6.92
(d, J ¼ 8.0 Hz, 1H), 5.24 (dd, J ¼ 8.0, 5.2 Hz, 1H), 4.06–3.97 (m,
2H), 2.90 (dd, J ¼ 15.2, 4.8, 1H), 2.82 (dd, J ¼ 15.2, 8.0, 1H), 1.15
(t, J ¼ 7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) d 177.0, 169.5,
144.8, 134.9, 134.4, 130.4, 129.4, 129.2, 128.7, 127.3, 125.9,
124.1, 120.7, 114.3, 61.3, 60.9, 40.0, 14.1; IR nmax/cmꢁ1 3319,
2979, 1718, 1617, 1373, 1094, 856, 788, 758, 686; HRMS
(ESI-TOF) m/z: [M + H]+ calcd for C18H18ClN2O2S 361.0772,
found 361.0773.
Ethyl 2-(3-(4-nitrophenyl)-2-thioxo-1,2,3,4-tetrahydroquin-
azolin-4-yl)acetate (4e). Following the typical procedure above,
compound 4e (364 mg, 98%) was obtained as a yellow solid: mp
155–156 ꢀC; 1H NMR (300 MHz, CDCl3) d 9.80 (s, 1H), 8.33 (d, J ¼
8.7 Hz, 2H), 7.67 (d, J ¼ 8.7 Hz, 2H), 7.28 (t, J ¼ 6.9 Hz, 1H), 7.18
(d, J ¼ 6.9 Hz, 1H), 7.10 (t, J ¼ 7.2 Hz, 1H), 6.98 (d, J ¼ 7.8 Hz,
1H), 5.33 (dd, J ¼ 7.5, 4.8 Hz, 1H), 4.08–3.97 (m, 2H), 2.90 (dd,
J ¼ 15.3, 5.1 Hz, 1H), 2.83 (dd, J ¼ 15.5, 7.8 Hz, 1H), 1.15 (t, J ¼
7.2 Hz, 3H); 13C NMR (75 MHz, CDCl3) d 176.8, 169.3, 149.2,
146.9, 134.1, 129.9, 129.6, 125.9, 124.8, 124.5, 120.6, 114.4, 61.4,
60.7, 40.1, 14.1; IR nmax/cmꢁ1 3296, 3068, 2993, 1708, 1607,
1526, 1373, 1350, 862, 758; HRMS (ESI-TOF) m/z: [M + H]+ calcd
for C18H18N3O4S 372.1013, found 372.1014.
Ethyl 2-(2-thioxo-3-(p-tolyl)-1,2,3,4-tetrahydroquinazolin-4-yl)-
acetate (4f). Following the typical procedure above, compound
4f (303 mg, 89%) was obtained as a white solid: mp 157–158 ꢀC;
1H NMR (400 MHz, CDCl3) d 8.48 (s, 1H), 7.30–7.26 (m, 5H), 7.16
(d, J ¼ 7.2 Hz, 1H), 7.08–7.05 (m, 1H), 6.84 (d, J ¼ 8.0 Hz, 1H),
5.23 (dd, J ¼ 8.4, 4.8 Hz, 1H), 4.05–3.96 (m, 2H), 2.92 (dd, J ¼
15.2, 4.8 Hz, 1H), 2.84 (dd, J ¼ 15.2, 8.4 Hz, 1H), 2.40 (s, 3H),
1.14 (t, J ¼ 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) d 177. 2,
169.7, 141.3, 138.4, 134.6, 130.2, 129.3, 128.4, 126.0, 123.8,
120.8, 114.1, 61.1, 61.0, 39.9, 21.4, 14.1; IR nmax/cmꢁ1 3335,
3120, 2927, 1716, 1615, 1506, 1463, 1373, 821, 763; HRMS (ESI-
TOF) m/z: [M + H]+ calcd for C19H21N2O2S 341.1318, found
341.1322.
Ethyl 2-(3-(2-chlorophenyl)-2-thioxo-1,2,3,4-tetrahydroquin-
azolin-4-yl)acetate (4j). Following the typical procedure above,
compound 4j (346 mg, 96%) was obtained as a white solid: mp
200–201 ꢀC; 1H NMR (400 MHz, CDCl3) d 9.01 (s, 1H), 7.64–7.62
(m, 1H), 7.55–7.53 (m, 1H), 7.40–7.25 (m, 3H), 7.17 (d, J ¼ 7.6
Hz, 1H), 7.07 (t, J ¼ 7.6 Hz, 1H), 6.90 (d, J ¼ 8.0 Hz, 1H), 5.16 (dd,
J ¼ 7.2, 5.6 Hz, 1H), 4.06–3.97 (m, 2H), 2.90 (dd, J ¼ 14.8, 5.2 Hz,
1H), 2.85 (dd, J ¼ 15.2, 7.6 Hz, 1H), 1.14 (t, J ¼ 7.2 Hz, 3H); 13
C
NMR (100 MHz, CDCl3) d 177.1, 169.6, 140.5, 134.3, 133.2, 131.6,
130.9, 129.9, 129.2, 127.3, 126.0, 124.1, 120.7, 114.3, 61.2, 59.4,
40.2, 14.1; IR nmax/cmꢁ1 3315, 2926, 1730, 1618, 1480, 1373,
1219, 753; HRMS (ESI-TOF) m/z: [M
18H18ClN2O2S 361.0772, found 361.0777.
Ethyl 2-(3-(2-uorophenyl)-2-thioxo-1,2,3,4-tetrahydroquin-
+
H]+ calcd for
C
azolin-4-yl)acetate (4k). Following the typical procedure above,
compound 4k (296 mg, 86%) was obtained as a white solid: mp
164–165 ꢀC; 1H NMR (400 MHz, CDCl3) d 9.02 (s, 1H), 7.40–7.23
(m, 5H), 7.15 (d, J ¼ 7.6 Hz, 1H), 7.07 (t, J ¼ 7.6 Hz, 1H), 6.90 (d,
J ¼ 8.0 Hz, 1H), 5.20 (m, 1H), 4.05–3.96 (m, 2H), 3.02–2.92 (m,
Ethyl 2-(3-(4-methoxyphenyl)-2-thioxo-1,2,3,4-tetrahydroqu-
inazolin-4-yl)acetate (4g). Following the typical procedure
above, compound 4g (310 mg, 87%) was obtained as a white
1H), 2.83 (dd, J ¼ 15.6, 8.4 Hz, 1H), 1.14 (t, J ¼ 7.2 Hz, 3H); 13
C
¼
1
NMR (100 MHz, CDCl3) d 176.9, 169.6 (J ¼ 31 Hz), 156.7 (1JCF
solid: mp 145–145.5 ꢀC; H NMR (300 MHz, CDCl3) d 9.68 (s,
212 Hz), 134.2 (3JCF ¼ 13 Hz), 133.0, 130.5 (3JCF ¼ 14 Hz), 130.1,
129.1, 125.6, 123.9 (2JCF ¼ 17 Hz), 120.8, 120.3, 117.0 (2JCF ¼ 20
Hz), 114.3, 61.0, 59.7, 40.3, 13.9; IR nmax/cmꢁ1 3321, 2898, 1724,
1602, 1518, 1464, 1175, 762; HRMS (ESI-TOF) m/z: [M + H]+ calcd
for C18H18FN2O2S 345.1068, found 345.1060.
1H), 7.33 (d, J ¼ 8.4 Hz, 2H), 7.23 (t, J ¼ 7.8 Hz, 1H), 7.12 (d, J ¼
7.2 Hz, 1H), 7.05–6.96 (m, 4H), 5.21 (dd, J ¼ 7.5, 4.8 Hz, 1H),
4.02–3.99 (m, 2H), 3.84 (s, 3H), 2.91 (dd, J ¼ 15.0, 5.1 Hz, 1H),
2.83 (dd, J ¼ 15.0, 8.4 Hz, 1H), 1.13 (t, J ¼ 6.9 Hz, 3H); 13C NMR
(100 MHz, CDCl3) d 177.3, 169.7, 159.1, 136.6, 134.3, 129.8,
129.2, 125.9, 123.8, 120.8, 114.7, 114.1, 61.2, 61.1, 55.6, 39.9,
14.1; IR nmax/cmꢁ1 3180, 3020, 1743, 1604, 1507, 1444, 1378,
1246, 1024, 836, 751; HRMS (ESI-TOF) m/z: [M + H]+ calcd for
Ethyl 2-(3-methyl-2-thioxo-1,2,3,4-tetrahydroquinazolin-4-yl)-
acetate (4l). Following the typical procedure above, compound
4l (257 mg, 97%) was obtained as a white solid: mp 77–78 ꢀC; 1H
NMR (400 MHz, CDCl3) d 9.51 (s, 1H), 7.23 (t, J ¼ 7.6 Hz, 1H),
7.10 (d, J ¼ 7.2 Hz, 1H), 7.01 (t, J ¼ 7.2 Hz, 1H), 6.96 (d, J ¼ 8.0
Hz, 1H), 5.03 (dd, J ¼ 7.2, 5.6 Hz, 1H), 4.11 (q, J ¼ 7.2 Hz, 2H),
3.52 (s, 3H), 2.81 (dd, J ¼ 15.2, 4.8 Hz, 1H), 2.65 (dd, J ¼ 15.2, 8.0
Hz, 1H), 1.20 (t, J ¼ 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) d
176.6, 170.1, 134.3, 129.1, 125.6, 123.7, 120.5, 113.7, 61.2, 59.1,
40.7, 39.3, 14.1; IR nmax/cmꢁ1 3192, 2978, 1720, 1602, 1367,
1203, 748; HRMS (ESI-TOF) m/z: [M + H]+ calcd for C13H17N2O2S
265.1005, found 265.1000.
C
19H21N2O3S 357.1267, found 357.1266.
Ethyl 2-(3-(3-methoxyphenyl)-2-thioxo-1,2,3,4-tetrahydroqu-
inazolin-4-yl)acetate (4h). Following the typical procedure
above, compound 4h (342 mg, 96%) was obtained as a white
solid: mp 117–118 ꢀC; 1H NMR (400 MHz, CDCl3) d 10.07 (s, 1H),
7.37 (t, J ¼ 8.0 Hz, 1H), 7.21 (t, J ¼ 7.6 Hz, 1H), 7.12 (d, J ¼ 7.6 Hz,
1H), 7.04–7.00 (m, 3H), 6.97–6.93 (m, 2H), 5.25 (dd, J ¼ 8.0, 4.8
Hz, 1H), 4.04–3.95 (m, 2H), 3.82 (s, 3H), 2.93 (dd, J ¼ 15.2, 4.8
Hz, 1H), 2.85 (dd, J ¼ 14.8, 8.4 Hz, 1H), 1.13 (t, J ¼ 7.2 Hz, 3H);
13C NMR (100 MHz, CDCl3) d 176.7, 169.5, 160.2, 144.7, 134.5,
130.0, 129.1, 125.7, 123.7, 120.9, 120.6, 114.5, 114.2, 113.9, 61.0,
60.8, 55.4, 40.0, 14.0; IR nmax/cmꢁ1 3122, 3202, 2939, 1730, 1608,
1497, 1441, 1047, 857, 785, 750, 692; HRMS (ESI-TOF) m/z: [M +
H]+ calcd for C19H21N2O3S 357.1267, found 357.1267.
Ethyl 2-(3-cyclohexyl-2-thioxo-1,2,3,4-tetrahydroquinazolin-
4-yl)acetate (4m). Following the typical procedure above,
compound 4m (295 mg, 89%) was obtained as a white solid: mp
1
ꢀ
76–78 C; H NMR (300 MHz, CDCl3) d 9.10 (s, 1H), 7.28–7.15
(m, 2H), 7.04–6.93 (m, 2H), 5.27–5.19 (m, 1H), 5.09 (dd, J ¼ 10.5,
3118 | RSC Adv., 2014, 4, 3113–3120
This journal is © The Royal Society of Chemistry 2014